Seqirus Presents New Clinical Data that Reinforce the Ability of MF59® Adjuvanted Seasonal and Pandemic Influenza Vaccines to Increase Immune Response - P&T Community

Seqirus Presents New Clinical Data that Reinforce the Ability of MF59® Adjuvanted Seasonal and Pandemic Influenza Vaccines to Increase Immune Response  P&T Community

SUMMIT, N.J., Aug. 30, 2019 /PRNewswire/ -- Seqirus, a global leader in influenza prevention, today presented data at the Options for the Control of Influenza ...



Comments

Popular posts from this blog

Washtenaw Co. sees sharp increase in whooping cough cases - Detroit News